Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PAK1 | Q13153 | 14/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3190443 | 0.93 | KMT2A (0.39) | KMT2APAK1BTK | |
| SCHEMBL22439077 | 0.87 | KMT2A (0.45) | KMT2APAK1AXLBTKEGFR | |
| SCHEMBL1694067 | 0.85 | JAK3 (0.44) | KMT2ABTKEGFR | |
| SCHEMBL1782933 | 0.83 | ALDH1A1 (0.51) | BTK | |
| SCHEMBL19654457 | 0.82 | KMT2A (0.55) | KMT2AAXLADORA3 | |
| SCHEMBL1784631 | 0.81 | PIN1 (0.48) | KMT2APAK1AXLBTKEGFR | |
| SCHEMBL16494261 | 0.81 | PAK1 (0.39) | KMT2APAK1BTKEGFRNOS1 | |
| SCHEMBL19665733 | 0.80 | MAPK8 (0.47) | BTKEGFRADORA3 | |
| SCHEMBL19665675 | 0.80 | HDAC3 (0.45) | AXLBTKEGFR | |
| SCHEMBL1783010 | 0.79 | KMT2A (0.65) | KMT2AAXLADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BUB1, BUB1B, TTBK1 | KMT2A 3089/4885PAK1 401/4885AXL 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.